about
Modulation of cellular apoptosis with apoptotic protease-activating factor 1 (Apaf-1) inhibitorsMiR-187 Targets the Androgen-Regulated Gene ALDH1A3 in Prostate Cancer.Demonstrating the importance of polymer-conjugate conformation in solution on its therapeutic output: Diethylstilbestrol (DES)-polyacetals as prostate cancer treatment.Cardiac differentiation is driven by NKX2.5 and GATA4 nuclear translocation in tissue-specific mesenchymal stem cells.Capturing "Extraordinary" Soft-Assembled Charge-Like Polypeptides as a Strategy for Nanocarrier Design.Metabolomics facilitates the discrimination of the specific anti-cancer effects of free- and polymer-conjugated doxorubicin in breast cancer models.Design of Poly-l-Glutamate-Based Complexes for pDNA Delivery.Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy.HIF-1α inhibition by diethylstilbestrol and its polyacetal conjugate in hypoxic prostate tumour cells: insights from NMR metabolomics.Tumor microenvironment-targeted poly-L-glutamic acid-based combination conjugate for enhanced triple negative breast cancer treatmentHypoxia Promotes Efficient Differentiation of Human Embryonic Stem Cells to Functional EndotheliumMesenchymal Stem Cells Provide Better Results Than Hematopoietic Precursors for the Treatment of Myocardial InfarctionCardiac Transcription Factors Driven Lineage-Specification of Adult Stem CellsP(HPMA)-block-P(LA) copolymers in paclitaxel formulations: Polylactide stereochemistry controls micellization, cellular uptake kinetics, intracellular localization and drug efficiencyPolyacetal-Based Combination Therapy for the Treatment of Prostate CancerDesign of Poly-l -Glutamate-Based Complexes for pDNA DeliveryCharacterization of triple-negative breast cancer preclinical models provides functional evidence of metastatic progression
P50
Q28582645-AD368C99-9C31-48E5-9B73-0D8389B02D91Q35602182-3AAB9311-0AEC-4EF0-953C-8C03E9D47459Q39415045-077FD410-ABC9-4AD5-90FD-19C9A4A2C291Q47254613-10245D04-81E9-49A8-9DD0-D22D6AE3E2B4Q48684399-0B70DAFF-452F-4E36-81D4-9F977A9B165EQ49968078-6EE65B17-B406-4E3D-A373-4CD37CE92768Q50099248-4964E4EE-37D7-45EA-A104-D8959DF8A2ABQ54223185-5C6D5B15-5B24-4BB2-B5B2-66C2112383ACQ54702281-938A870D-3218-4662-B337-A9DABB87D410Q57073528-A5DE1643-A0CB-4127-8E5D-4951BFAB8025Q57310803-9708E871-E2EC-4DC0-8992-A75A1B024DADQ59938198-9AB01C59-2386-4869-AEE5-DBB102ABEB92Q59938199-AE03397D-BD50-4F67-B13A-CE839CFD391EQ62116890-791F33E6-7E6B-4E90-BF7E-7339777571DEQ63209065-5FCB67FA-2E39-41E2-961C-FB803AC956FEQ63209202-AB43C759-7AD6-486C-8946-84904B309F1BQ92297302-6E7A3BA7-16A1-4542-A8D6-140D84A35B09
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ana Armiñán
@ast
Ana Armiñán
@en
Ana Armiñán
@es
Ana Armiñán
@nl
type
label
Ana Armiñán
@ast
Ana Armiñán
@en
Ana Armiñán
@es
Ana Armiñán
@nl
prefLabel
Ana Armiñán
@ast
Ana Armiñán
@en
Ana Armiñán
@es
Ana Armiñán
@nl
P106
P21
P31
P496
0000-0003-2821-8477